Peritoneal cancer occurs when cancer spreads to the lining of the abdominal cavity, known as the peritoneum. It may arise from primary peritoneal cancer or spread from cancers of the colon, stomach, appendix, ovaries, or other abdominal organs. Traditionally, peritoneal cancers were considered difficult to treat, but advances such as Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) have significantly improved treatment options for carefully selected patients.
Dr. Ramkishan Nag specializes in advanced surgical oncology and offers comprehensive evaluation for patients who may benefit from cytoreductive surgery combined with HIPEC or PIPAC as part of a multidisciplinary cancer treatment plan.
HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is an advanced treatment performed immediately after cytoreductive surgery. After removing all visible tumors from the abdominal cavity, a heated chemotherapy solution is circulated throughout the abdomen to destroy microscopic cancer cells that may remain.
PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) is a minimally invasive treatment in which chemotherapy is delivered into the abdominal cavity as a pressurized aerosol through laparoscopic surgery. This approach improves drug distribution and tissue penetration while using lower chemotherapy doses.
HIPEC and PIPAC may be considered for selected patients with:
Not every patient with peritoneal cancer is suitable for HIPEC or PIPAC. Careful evaluation with imaging studies, overall health assessment, cancer staging, and multidisciplinary discussion helps determine the most appropriate treatment strategy for each individual.
Dr. Ramkishan Nag has advanced fellowship training in Peritoneal Surface Malignancies and extensive experience in cytoreductive surgery, HIPEC, and modern cancer surgery. He provides evidence-based, patient-centered care using the latest treatment techniques to help patients achieve the best possible outcomes.
HIPEC and PIPAC have expanded the treatment possibilities for patients with peritoneal cancers. When performed in carefully selected patients by an experienced surgical oncology team, these advanced therapies can improve disease control, quality of life, and long-term outcomes. Early evaluation by a specialist is essential to determine whether these innovative treatments are appropriate for your condition.
HIPEC is performed after surgical removal of visible tumors using heated chemotherapy circulated inside the abdomen, whereas PIPAC delivers chemotherapy as a pressurized aerosol through minimally invasive laparoscopic surgery.
These treatments may be suitable for selected patients with colorectal, appendiceal, ovarian, gastric, primary peritoneal cancers, and certain cases of peritoneal mesothelioma.
Yes. HIPEC uses heated chemotherapy delivered directly into the abdominal cavity after surgery, allowing high local drug concentration while limiting exposure to the rest of the body.
No. Patient selection depends on the type of cancer, extent of disease, overall health, and treatment goals. A thorough evaluation is required before recommending these procedures.
Dr. Ramkishan Nag has specialized fellowship training in Peritoneal Surface Malignancies and expertise in Cytoreductive Surgery, HIPEC, and advanced surgical oncology. He offers personalized, evidence-based care with a multidisciplinary approach for the best possible patient outcomes.